Peregrine Pharma researchers report Phospholipid-targeted antibodies fused with cytokines reduce tumor growth in animals by over 90% (PPHM) 1.24 +0.02 : Co reported new research showing that a fusion protein approach that combines two proprietary Peregrine technology platforms -- its Vascular Targeting Agent and anti- phospholipid technologies -- has demonstrated significant anti-tumor potential. In a presentation at the Angiogenesis and Vascular Targeting Agents Conference, researchers presented data showing that a fusion protein combining an antibody from Peregrine's anti-phospholipid therapy program with immunostimulatory cytokines such as interferon or interleukin reduced tumor growth in animal cancer models by more than 90%, with no discernable increase in toxicity. These studies represent an important validation of a new class of compounds in Peregrine's proprietary VTA platform, which uses agents targeted to tumor blood vessels to kill tumors by depriving them of the nutrients and oxygen needed for continued growth..
Market Data 
Markets 
AI
